Bull or Bear, Seeking Alpha is there
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

By creating an account using any of the options above, you agree to the Terms of Use & Privacy Policy

Bull or Bear, Seeking Alpha is there
Markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings.

RGNX REGENXBIO Inc.
Latest Stock Analysis

$9.15-0.05 (-0.54%)4:00 PM 04/25/25

NASDAQ | $USD | Post-Market: $9.05 -0.10 (-1.09%) 7:23 PM

Summary Ratings Financials Earnings Dividends Valuation Growth Profitability Momentum Peers Options Charting

Transcripts & InsightsTranscripts & Insights

SEC FilingsSEC Filings

Press ReleasesPress Releases

Related AnalysisRelated Analysis

Analysis

Ratings:

Select Ratings

Date Range:

Stocks To Watch: Investors Look For Edges Amid Inflation, Rates, Earnings Challenges

Wall Street Week AheadSat, Oct. 01, 202214 Comments

Regenxbio: A Transformative Year

BioSci Capital PartnersThu, Sep. 15, 20226 Comments

Regenxbio: Updates To Thesis, Gene Therapy Pioneer Moving To Late-Stage Development

Jonathan FaisonMon, Aug. 29, 20227 Comments

Regenxbio: Patience And Regular Homework Are Keys

Avisol Capital PartnersTue, Jul. 12, 20223 Comments

Stocks To Watch: Retail Heavyweights Report, Block And Moderna Events

Wall Street Week AheadSat, May 14, 202211 Comments

Regenxbio: Is The Ultimate Catalyst Coming?

BioSci Capital PartnersWed, Apr. 20, 202211 Comments

Regenxbio: Suprachoroidal Data Is Still The Key

Avisol Capital PartnersTue, Mar. 08, 2022

Regenxbio: Accumulating For The Long Haul

Avisol Capital PartnersSun, Dec. 26, 20216 Comments

Regenxbio: Unlocking Value Through The Mega AbbVie Partnership

BioSci Capital PartnersMon, Sep. 27, 202117 Comments

Regenxbio: Suprachoroidal Data May Impress

Sage AdvisorsTue, Jul. 06, 20218 Comments

Regenxbio: An Overlooked Gene Therapy Innovator

BioSci Capital PartnersFri, May 14, 202110 Comments

Regenxbio: Better Investment Case Than Adverum

Avisol Capital PartnersWed, May 12, 202114 Comments

Regenxbio: Championing Gene Therapy

BioSci Capital PartnersSat, Dec. 19, 202029 Comments

Regenxbio RGX-121 Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma

Avisol Capital PartnersTue, Oct. 06, 20201 Comment

Regenxbio Advances Clinical Program, And Other News: The Good, Bad And Ugly Of Biopharma

Avisol Capital PartnersSat, Oct. 03, 2020

Regenxbio: More Robust Data For Wet AMD

BioSci Capital PartnersSun, Sep. 13, 202022 Comments

The Wet AMD Gene Therapy Race - Adverum Biotechnologies Vs. Regenxbio

Sage AdvisorsFri, May 29, 202028 Comments

Regenxbio Is A Leader In Gene Therapies - A Case Where The Platform Is Worth More Than The Pipeline

Numenor CapitalFri, Apr. 24, 202014 Comments

Regenxbio: A Growth Stock For The Coronavirus Bear Market

BioSci Capital PartnersWed, Apr. 01, 20203 Comments

Regenxbio: Fairly Valued Given The Current Risks But Could Have Eye-Watering Upside

Value KickerTue, Dec. 10, 20197 Comments

Regenxbio: Revisiting This Gene Therapy 'Picks And Shovels' Play

Jonathan FaisonWed, Dec. 04, 201918 Comments

Regenxbio: Amid Temporary Difficulty Is A Buying Opportunity

BioSci Capital PartnersFri, Nov. 15, 201915 Comments

Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections

Terry ChrisomalisWed, Oct. 30, 20198 Comments

Investing Groups

Portfolios

Find & Compare

Subscriptions

RGNX REGENXBIO Inc.
Latest Stock Analysis

Analysis

People Also Follow

Similar to RGNX

ETFs Holding RGNX

RGNX REGENXBIO Inc.Latest Stock Analysis

Analysis

People Also Follow

Similar to RGNX

ETFs Holding RGNX

RGNX REGENXBIO Inc.
Latest Stock Analysis